000131822 001__ 131822
000131822 005__ 20240229105015.0
000131822 0247_ $$2doi$$a10.1007/s00520-017-3875-5
000131822 0247_ $$2pmid$$apmid:28963591
000131822 0247_ $$2ISSN$$a0941-4355
000131822 0247_ $$2ISSN$$a1433-7339
000131822 0247_ $$2altmetric$$aaltmetric:26871380
000131822 037__ $$aDKFZ-2018-00117
000131822 041__ $$aeng
000131822 082__ $$a610
000131822 1001_ $$0P:(DE-He78)d05b24af674d8ef2c455634434b67770$$aZimmer, Philipp$$b0$$eFirst author$$udkfz
000131822 245__ $$aEight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial.
000131822 260__ $$aBerlin$$bSpringer$$c2018
000131822 3367_ $$2DRIVER$$aarticle
000131822 3367_ $$2DataCite$$aOutput Types/Journal article
000131822 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521453102_12159
000131822 3367_ $$2BibTeX$$aARTICLE
000131822 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131822 3367_ $$00$$2EndNote$$aJournal Article
000131822 520__ $$aPhysical activity is supposed to decrease mortality of colorectal cancer (CRC) and is suggested to reduce side-effects of the disease and its treatment. However, the knowledge about the influence of exercise interventions on patients suffering from CRC and metastasized CRC (mCRC) is still sparse. One frequently observed side effect in mCRC is chemotherapy-induced peripheral neuropathy (CIPN). This randomized controlled trial investigated the influence of a supervised exercise program on CIPN in mCRC.Thirty patients (stage IV) undergoing outpatient palliative treatment including a median of 23.5 chemotherapy cycles of various regimens were randomly assigned to an intervention or control group (IG, n = 17; CG, n = 13). The IG participated in an eight-week supervised exercise program, including endurance, resistance and balance training (2×/week for 60 min) whereas the CG received written standard recommendations to obtain physical fitness. CIPN was assessed using the FACT/GOG-NTX questionnaire. Moreover, endurance capacity (6MWT), strength (h1RM) and balance (GGT-Reha) were evaluated before (t 0) and after (t 1) the intervention as well as after 4 weeks follow-up (t2).Neuropathic symptoms remained stable in the IG over time, while CIPN significantly worsened in the CG from t 0 to t 1 and t 0 to t 2. In contrast to the CG, the IG significantly improved in strength and balance function. Changes in CIPN correlated with changes in balance.This is the first investigation showing positive effects of a multimodal exercise program on CIPN, balance and strength on mCRC patients in a palliative setting, thereby consequently increasing patients` quality of life. The results support earlier findings stating a positive influence of balance exercise on CIPN.
000131822 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000131822 588__ $$aDataset connected to CrossRef, PubMed,
000131822 7001_ $$aTrebing, Sina$$b1
000131822 7001_ $$aTimmers-Trebing, Ursula$$b2
000131822 7001_ $$aSchenk, Alexander$$b3
000131822 7001_ $$aPaust, Rainer$$b4
000131822 7001_ $$aBloch, Wilhelm$$b5
000131822 7001_ $$aRudolph, Roland$$b6
000131822 7001_ $$aStreckmann, Fiona$$b7
000131822 7001_ $$aBaumann, Freerk T$$b8
000131822 773__ $$0PERI:(DE-600)1463166-0$$a10.1007/s00520-017-3875-5$$gVol. 26, no. 2, p. 615 - 624$$n2$$p615 - 624$$tSupportive care in cancer$$v26$$x1433-7339$$y2018
000131822 909CO $$ooai:inrepo02.dkfz.de:131822$$pVDB
000131822 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d05b24af674d8ef2c455634434b67770$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000131822 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000131822 9141_ $$y2018
000131822 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000131822 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131822 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131822 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131822 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSUPPORT CARE CANCER : 2015
000131822 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000131822 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000131822 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131822 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000131822 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131822 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131822 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000131822 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000131822 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000131822 980__ $$ajournal
000131822 980__ $$aVDB
000131822 980__ $$aI:(DE-He78)G210-20160331
000131822 980__ $$aUNRESTRICTED